Fundraising Fox
Vaderis Therapeutics
4 known investors
Find your way into Vaderis Therapeutics
Sign up to find every way you can get introduced to Vaderis Therapeutics
- Your email: who you already know at Vaderis Therapeutics, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Vaderis Therapeutics team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Vaderis develops a first-of-its-kind oral therapy for hereditary hemorrhagic telangiectasia (HHT), a rare vascular disease with no existing approved treatments. The company is led by scientists and clinicians focused on creating therapeutic options for patients with underserved rare diseases.
Investors · 4
How we know: Droia Ventures's portfolio page · the VCSheet dataset · Not right? Tell us
How we know: Medicxi's portfolio page · funding news · Not right? Tell us
How we know: funding news · prnewswire.com · Not right? Tell us
How we know: am.gs.com · Not right? Tell us
Funding
SEC filings, press & company announcements$152M disclosed across 1 round · 2026
- $152MSeries BAug 2026 · 4 sources
EQT Life Sciences, Goldman Sachs Asset Management
Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does Vaderis Therapeutics do?
- Vaderis develops a first-of-its-kind oral therapy for hereditary hemorrhagic telangiectasia (HHT), a rare vascular disease with no existing approved treatments. The company is led by scientists and clinicians focused on creating therapeutic options for patients with underserved rare diseases.
- Who are Vaderis Therapeutics's investors?
- Vaderis Therapeutics's investors include Droia Ventures, Medicxi, EQT Life Sciences, Goldman Sachs.
- How much funding has Vaderis Therapeutics raised?
- Vaderis Therapeutics has disclosed $152M raised across 1 round.